Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E E Voest

Showing results (1-10 of 110) with videos related to

Pageof 11
Sort By:
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 15, 2006
Neovascularization: the Achilles' heel of tumors?E E Voest
Anti-Cancer Drugs|September 1, 1996
Inhibitors of angiogenesis in a clinical perspectiveE E Voest
Seminars in Oncology|March 20, 2001
The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancerM Los, E E Voest
Cell|March 29, 2024
Generating and using real-world data: A worthwhile uphill battleK Verkerk, E E Voest
ESMO Open|March 20, 2025
Authors response to Letter re: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP) molecular complexity and response to targeted therapyK Verkerk, E E Voest
The Cancer Journal From Scientific American|May 1, 1997
Microvessel density and outcome of adjuvant treatment of breast cancer patientsE E Voest, G H Blijham
Molecular and Cellular Endocrinology|November 15, 2002
Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approachesR J A van Moorselaar, E E Voest
European Journal of Cancer (Oxford, England : 1990)|August 26, 2000
No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancerA Reijerkerk, E E Voest, M F Gebbink
European Journal of Clinical Investigation|September 1, 1999
New strategies in anti-vascular cancer therapyH J Bloemendal, T Logtenberg, E E Voest
Annals of Internal Medicine|March 15, 1994
Iron-chelating agents in non-iron overload conditionsE E Voest, G Vreugdenhil, J J Marx
Pageof 11

Showing results (1-10 of 110) with videos related to

Sort By:
Pageof 11
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 15, 2006
Neovascularization: the Achilles' heel of tumors?E E Voest
Anti-Cancer Drugs|September 1, 1996
Inhibitors of angiogenesis in a clinical perspectiveE E Voest
Seminars in Oncology|March 20, 2001
The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancerM Los, E E Voest
Cell|March 29, 2024
Generating and using real-world data: A worthwhile uphill battleK Verkerk, E E Voest
ESMO Open|March 20, 2025
Authors response to Letter re: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP) molecular complexity and response to targeted therapyK Verkerk, E E Voest
The Cancer Journal From Scientific American|May 1, 1997
Microvessel density and outcome of adjuvant treatment of breast cancer patientsE E Voest, G H Blijham
Molecular and Cellular Endocrinology|November 15, 2002
Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approachesR J A van Moorselaar, E E Voest
European Journal of Cancer (Oxford, England : 1990)|August 26, 2000
No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancerA Reijerkerk, E E Voest, M F Gebbink
European Journal of Clinical Investigation|September 1, 1999
New strategies in anti-vascular cancer therapyH J Bloemendal, T Logtenberg, E E Voest
Annals of Internal Medicine|March 15, 1994
Iron-chelating agents in non-iron overload conditionsE E Voest, G Vreugdenhil, J J Marx
Pageof 11